Consider this a thought experiment. There is no announced or rumored deal for Hims & Hers Health (NYSE:HIMS). Still, the setup begs the question. The telehealth platform now has 2.6 million subscribers, a $7.2 billion market cap, and a stock that has declined 50.9% over the past year to $30.82. Q1 2026 revenue of $608.10 million missed expectations as the GLP-1 pivot compressed gross margin to 65%. CEO Andrew Dudum still insists “2026 is a defining year for Hims & Hers. We’re not just growing, we’re pulling away from the field.” That mix, wounded price plus intact subscriber base, is exactly the profile strategics circle.
Ranked: Longest Shot to Cleanest Fit
4. Pfizer (NYSE:PFE | PFE Price Prediction). At a $141.3 billion market cap, Pfizer could absorb Hims easily, and Albert Bourla has publicly leaned into “oncology and obesity, two areas where I believe Pfizer is positioned to lead.” The drawback: Pfizer is a manufacturer, not a DTC operator, and pharma owning a prescriber platform invites channel-conflict scrutiny.
3. CVS Health (NYSE:CVS). CVS is up 30.5% year to date with a $132.2 billion cap and Aetna, Caremark, and retail pharmacy under one roof. Strategic fit is clear. The drawback is bandwidth: integrating another consumer brand while running an insurer is a heavy lift.
2. UnitedHealth (NYSE:UNH). Optum Rx generated $38.3 billion in Q2 revenue, and Stephen Hemsley has been preaching simplification. Adding a 2.6-million-member DTC front door to Optum is elegant. The drawback is antitrust: after recent Optum deals, another consumer-health tuck-in draws regulator eyes.
1. Amazon (NASDAQ:AMZN). Amazon Pharmacy grew its new customer base by more than 2x in H1, and Andy Jassy noted AWS is “growing 36.7% year-over-year in Q2, our fastest growth in 18 quarters.” With a $3.0 trillion market cap, Hims is a rounding error. The cleanest strategic overlay, though FTC posture on Amazon health is the wildcard.
Notably absent is Walgreens Boots Alliance, which is being taken private by Sycamore Partners and is effectively out of the buyer pool.
Where Private Equity Fits
Private equity could underwrite a take-private deal on the growth story, with $2.80 billion to $3.00 billion in FY2026 revenue guidance and adjusted EBITDA of $275 million to $350 million. The obstacle is leverage: Hims already carries roughly $1 billion in convertible debt.
What to Watch
Two structural realities dominate. First, Dudum is identified in filings as a “10% owner” and holds super-voting control; no deal happens without his blessing, and his June 15 net acquisition of 154,991 shares hardly suggests a seller. Second, Hims is itself an acquirer, with the proposed Eucalyptus deal expected to close mid-2026. Companies buying international platforms rarely sell weeks later. Keep an eye on the stock, but treat any takeout chatter as speculation until governance moves.
Contact [email protected] for any questions or corrections.
Top Gaining Stocks
Top Losing Stocks